Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033

Irreversible inhibitors of the epidermal growth factor receptor (EGFR) are showing promise in clinical trials. This report is the first to show that inhibition of the EGFR tyrosine kinase by an irreversible binder synergizes with cisplatin, at least in EGFR-overexpressing tissue culture cell lines in vitro. Unlike previous synergies demonstrated between ErbB2 blockade and DNA-damaging drugs, the synergy between the irreversible EGFR inhibitor and cisplatin does not appear to involve the repair of DNA-cisplatin adducts. Given the current clinical data, this combination may be of more than theoretical interest.

[1]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  O. H. Chan,et al.  Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. , 2000, Journal of medicinal chemistry.

[3]  L. Norton,et al.  Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Baselga,et al.  Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. , 1999, Drugs of today.

[5]  D. Slamon,et al.  Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. , 1999, Seminars in oncology.

[6]  R. Perona,et al.  Lack of c‐Jun activity increases survival to cisplatin , 1999, FEBS letters.

[7]  D. W. Fry,et al.  Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. , 1999 .

[8]  R. Todd,et al.  Epidermal growth factor receptor (EGFR) biology and human oral cancer. , 1999, Histology and histopathology.

[9]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[10]  G. Tortora,et al.  Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[12]  J. Essigmann,et al.  Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. , 1998, Biochemistry.

[13]  R. Finn,et al.  Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs , 1998, Oncogene.

[14]  W. Denny,et al.  Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Moras,et al.  Cisplatin‐ and UV‐damaged DNA lure the basal transcription factor TFIID/TBP , 1997, The EMBO journal.

[16]  A. Giaccia,et al.  Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis , 1997, Molecular and cellular biology.

[17]  S. Richard,et al.  Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185erbB-2 is dependent on the ras signaling pathway , 1997, Oncogene.

[18]  T. Lindahl,et al.  DNA excision repair pathways. , 1997, Current opinion in genetics & development.

[19]  J. Mendelsohn,et al.  Epidermal growth factor receptor family and chemosensitization. , 1997, Journal of the National Cancer Institute.

[20]  W. Denny,et al.  Mutagenic and carcinogenic properties of platinum-based anticancer drugs. , 1996, Mutation research.

[21]  B. Sanderson,et al.  Mutagenic damage to mammalian cells by therapeutic alkylating agents. , 1996, Mutation research.

[22]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[23]  J. Mymryk,et al.  Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Arteaga,et al.  p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. , 1994, Cancer research.

[25]  D. Slamon,et al.  Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. , 1994, Oncogene.

[26]  H. Modjtahedi,et al.  The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review). , 1994, International journal of oncology.

[27]  J. Baselga,et al.  Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. , 1993, Cancer research.

[28]  J. Djiane,et al.  Beta-galactosidase and chloramphenicol acetyltransferase assays in 96-well plates. , 1993, BioTechniques.

[29]  J. Gralla,et al.  Differential effects of cisplatin on the expression of chimeric marker genes in CV-1 cells. , 1992, Biochemical pharmacology.

[30]  R. Weichselbaum,et al.  cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. , 1992, Cancer research.

[31]  S. Lin-Chao,et al.  Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II). , 1991, Cancer research.

[32]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[33]  I. Pastan,et al.  Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. , 1987, Science.

[34]  A. Sancar,et al.  DNA excision repair assays. , 1997, Progress in nucleic acid research and molecular biology.

[35]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[36]  E. Friedberg.  DNA Excision Repair Pathways , 2022 .